All News

The top 5 most-read news content for 2023 featured COVID-19 vaccination uptake and its relation to HIV viral suppression, those more likely to get vitamin D supplements, and recurrence of Clostridioides difficile infection.

In 2023, adalimumab biosimilars took center stage in the biosimilar space due to 8 long-anticipated products finally launching.

David Fajgenbaum, MD, MBA, MSc, cofounder of Every Cure, shared that the organization is able to reduce clinical trial costs to $1 to $5 million per drug trial, and that clinical trials are not always necessary to expand a drug's indication.

In our coverage of myasthenia gravis this year, the top developments show the effects of COVID-19 continue to be uncovered, a new FDA approval for generalized disease, and assessing patient outcomes following uncontrolled disease and respiratory distress.

Our top coverage from this year’s Revolutionizing Atopic Dermatitis (RAD) conference highlighted the evolving therapy landscape for patients with AD.

The Center on Health Equity and Access offers updates on recent news, breakthroughs in research, and ongoing initiatives aimed at tackling health care disparities and enhancing overall access to top-notch care.

Following the FDA approval of vonoprazan in the treatment of erosive esophagitis, Dr Colin Howden discussed important information about the new therapy.

The government of Australia’s pricing policy links the price of new medications with similar safety and efficacy, resulting in significant savings over the first 3 years after the etanercept biosimilar Brenzys was introduced.

This year’s most-read spinal muscular atrophy(SMA) articles explored mental health, new technologies, caregiver well-being, and more.

Top coverage from the National Association of Managed Care Physicians (NAMCP) Spring Managed Care Forum 2023 included sessions on value-based care implementation and best treatment practices.

Dose modifications of talquetamab improved on-target adverse effects while maintaining responses for patients with relapsed/refractory multiple myeloma.

Two doses of batoclimab were evaluated for their effectiveness in patients with generalized myasthenia gravis (MG) who were seropositive.

The bipartisan bill would help lower Medicare costs and improve quality of care, according to the National Association of ACOs.

Also known as Sanfilippo syndrome, this rare genetic syndrome has no known cures and what current treatment options are available are expensive and limited in supply.

This year’s most-read articles on autoimmune diseases explored comorbidities with cardiovascular disease, the value of new forms of monitoring and therapy, and more.

A vaccine is showing promising results in treating melanoma; the Biden administration will implement inflation penalties on dozens of drugmakers to reduce out-of-pocket costs for Medicare recipients; the CDC issued an alert urging health care providers to increase immunization coverage for influenza, COVID-19, and respiratory syncytial virus (RSV).

The results indicated that a substantial proportion of patients, particularly in rural, less educated, and elderly demographics, are insufficiently informed about novel MM treatments, including chimeric antigen receptor (CAR) T-cell therapies and bispecific antibody alternatives.

The approval of belzutifan, an oral hypoxia-inducible factor-2 alpha inhibitor, provides a new option for patients with advanced renal cell carcinoma (RCC) following treatment with a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).

The addition of serplulimab to carboplatin and nab-paclitaxel significantly prolonged survival vs chemotherapy alone when used in the first-line treatment of patients with previously untreated locally advanced or metastatic squamous non–small cell lung cancer.

Trastuzumab administered subcutaneously delivered unique immunomodulation effects vs intravenous trastuzumab in patients with treatment-naïve HER2-positive (HER2+) breast cancer

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Givinostat, a histone deacetylase inhibitor from Italfarmaco, was supported by data from the phase 3 EPIDYS study, a randomized, double-blind, placebo-controlled, multicenter trial investigating the agent vs placebo.

The treatment developed by Amgen could be the first therapeutic option approved for third-line treatment of advanced small cell lung cancer (SCLC).

Skeletal muscle proved to be significant in calculating chemotherapy toxicities in nonmetastatic colorectal cancer (CRC).

A new report from AHIP shows that Medicare Advantage outperformed traditional Medicare on several clinical quality measures, including preventive screenings. However, debate continues over these plans’ cost efficiency and impact on the financial sustainability of rural hospitals.

New research shows that adding navy beans to one’s usual diet may be a viable dietary strategy for modulating the gut microbiome and regulating host markers associated with metabolic obesity and colorectal cancer.

This year’s most-read articles on multiple sclerosis (MS) explored the emergence of new medications, modes of therapy, and predictive tools in the study of MS.

The rate of invasive pneumococcal disease in children plummeted by 72% from 2002 to 2021; health care spending in the United States rose 4.1% in 2022 to $4.5 trillion; roughly two-thirds of Americans who have a mental health condition were unable to access treatment in 2021 despite having health insurance.

While past studies have shown the connection between poor sleep and job performance, this research dives deeper into the experience of this specific population.

Children with sickle cell disease and their caregivers experience an increased burden on health-related quality of life (HRQoL) due to the frequency of vaso-occlusive crises (VOCs).